AIDS

Exploring definitions of retention in care for people living with HIV in the United States in the modern treatment era.  36:1181-1189. 2022

Racial and ethnic disparities in coronavirus disease 2019 disease incidence independent of comorbidities, among people with HIV in the United States.  36:1095-1103. 2022

Risk factors for atrial fibrillation in a multicenter United States clinical cohort of people with HIV infection.  36:903-905. 2022

Anal cancer incidence in men with HIV who have sex with men: are black men at higher risk?.  36:657-664. 2022

Effect of antiretroviral therapy care interruptions on mortality in children living with HIV.  36:729-737. 2022

Peripheral artery disease and physical function in women with and without HIV.  36:347-354. 2022

Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization.  36:257-265. 2022

Opioid use disorder: a neglected human immunodeficiency virus risk in American adolescents.  35:2237-2247. 2021

Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/hepatitis C virus coinfected women.  35:1433-1438. 2021

Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV.  35:1191-1199. 2021

Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls.  35:369-380. 2021

Pharmacokinetics and safety of maraviroc in neonates.  35:419-427. 2021

Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV.  35:407-417. 2021

Advanced HIV disease during the ‘Treat All’ era in Botswana.  34:2321-2323. 2020

Characteristics and outcomes of adolescents living with perinatally acquired HIV within Southern Africa.  34:2275-2284. 2020

Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options.  34:2051-2059. 2020

Effects of an intervention on internalized HIV-related stigma for individuals newly entering HIV care.  34:S73-S82. 2020

Internalized HIV stigma predicts subsequent viremia in US HIV patients through depressive symptoms and antiretroviral therapy adherence.  34:1665-1671. 2020

Internalized HIV stigma predicts subsequent viremia in US HIV patients through depressive symptoms and antiretroviral therapy adherence..  34:1665-1671. 2020

Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities.  34:559-567. 2020

Cytomegalovirus-vectored vaccines for HIV and other pathogens.  34:335-349. 2020

Female genital tract shedding of HIV-1 is rare in women with suppressed HIV-1 in plasma.  34:39-46. 2020

Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis.  33:2197-2203. 2019

Social harms in female-initiated HIV prevention method research: State of the evidence.  33:2237-2244. 2019

Contributions of HIV, hepatitis C virus, and traditional vascular risk factors to peripheral artery disease in women.  33:2025-2033. 2019

Déjà vu all over again..  33:2097-2098. 2019

HIV stigma and viral load among African-American women receiving treatment for HIV.  33:1511-1519. 2019

HIV stigma and viral load among African-American women receiving treatment for HIV..  33:1511-1519. 2019

Poverty stigma is associated with suboptimal HIV care and treatment outcomes among women living with HIV in the United States.  33:1379-1384. 2019

Kidney disease in Africans with HIV and tuberculosis.  33:1207-1213. 2019

Longitudinal association between internalized HIV stigma and antiretroviral therapy adherence for women living with HIV: The mediating role of depression.  33:571-576. 2019

Increased influenza-specific antibody avidity in HIV-infected women compared with HIV-infected men on antiretroviral therapy.  33:33-44. 2019

Viremia copy-years and mortality among combination antiretroviral therapy-initiating HIV-positive individuals: how much viral load history is enough?.  32:2547-2556. 2018

Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation.  32:1389-1401. 2018

Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ :  CD8+ ratio..  32:1361-1367. 2018

Long-term trends in CD4 cell counts, CD8 cell counts, and the CD4: CD8 ratio: ART Cohort Collaboration (ART-CC) Study. 2018

Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.  32:729-737. 2018

Trends in antiretroviral therapy prescription, durability and modification: New drugs, more changes, but less failure.  32:347-355. 2018

Virologic suppression and CD4 + cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens.  32:261-266. 2018

Beyond binary retention in HIV care: Predictors of the dynamic processes of patient engagement, disengagement, and re-entry into care in a US clinical cohort.  32:2217-2225. 2018

Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.  32:2507-2516. 2018

Evaluating outcomes of mother-infant pairs using dolutegravir for HIV treatment during pregnancy.  32:2017-2021. 2018

HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy.  32:2151-2159. 2018

Progressive lentivirus infection induces natural killer cell receptor-expressing B cells in the gastrointestinal tract.  32:1571-1578. 2018

Racial differences in human papilloma virus types amongst United States women with HIV and cervical precancer.  32:2821-2826. 2018

Viremia copy-years and mortality among combination antiretroviral therapy-initiating HIV-positive individuals: How much viral load history is enough?.  32:2547-2556. 2018

Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries.  31:1697-1707. 2017

CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.  31:1129-1136. 2017

Cervical cancer screening intervals and management for women living with HIV: A risk benchmarking approach.  31:1035-1044. 2017

Relationship between ever reporting depressive symptoms and all-cause mortality in a cohort of HIV-infected adults in routine care.  31:1009-1016. 2017

Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy.  31:787-795. 2017

Smoking, HIV, and risk of pregnancy loss.  31:553-560. 2017

Interpreting the influence of race and cognitive activity on neurocognition in adults aging with HIV.  31:443-445. 2017

Increased glucose transporter-1 expression on intermediate monocytes from HIV-infected women with subclinical cardiovascular disease.  31:199-205. 2017

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.  30:1229-1238. 2016

Assessing efficacy of a retention-in-care intervention among HIV patients with depression, anxiety, heavy alcohol consumption and illicit drug use.  30:1111-1119. 2016

A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus.  30:869-878. 2016

High rate of lymphoma among a UK cohort of adolescents with vertically acquired HIV-1 infection transitioning to adult care in the era of antiretroviral therapy.  30:153-156. 2016

Cost considerations in the current antiretroviral era.  30:2215-2219. 2016

Normal T-cell activation in elite controllers with preserved CD4 + T-cell counts.  29:2245-2254. 2015

Disclosure of pharmacokinetic drug results to understand nonadherence.  29:2161-2171. 2015

Intimate partner violence and engagement in HIV care and treatment among women: A systematic review and meta-analysis.  29:2183-2194. 2015

The effect of antidepressant treatment on HIV and depression outcomes: Results from a randomized trial.  29:1975-1986. 2015

Examining the association between male circumcision and sexual function: Evidence from a British probability survey.  29:1411-1416. 2015

Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients..  29:373-383. 2015

Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.  29:1113-1115. 2015

Testosterone replacement therapy among HIV-infected men in the CFAR network of integrated clinical systems.  29:77-81. 2015

Time above 1500 copies: A viral load measure for assessing transmission risk of HIV-positive patients in care.  29:947-954. 2015

Mitochondrial DNA variation and virologic and immunological HIV outcomes in African Americans.  28:1871-1878. 2014

Decline in locomotor functions over time in HIV-infected patients.  28:1531-1532. 2014

Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.  28:979-987. 2014

Efficacy and safety of Maraviroc vs. Efavirenz in treatment-naive patients with HIV-1: 5-year findings.  28:717-725. 2014

Deficient synthesis of class-switched, HIVneutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen.  28:2201-2211. 2014

Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.  28:2627-2631. 2014

HIV-infected women on antiretroviral treatment have increased mortality during pregnant and postpartum periods.  27. 2013

Association of early HIV viremia with mortality after HIV-associated lymphoma.  27:2365-2373. 2013

Clinical, radiological and laboratory features of human metapneumovirus lower respiratory tract infection in HIV-positive patients: A case series.  27:2317-2319. 2013

Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy.  27:1593-1602. 2013

Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009..  27:803-813. 2013

Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.  27:221-225. 2013

Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection.  26:2257-2259. 2012

Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.  26:1907-1915. 2012

Replication of RYR3 gene polymorphism association with cIMT among HIV-infected whites.  26:1571-1573. 2012

The association between Mycoplasma genitalium and HIV-1 acquisition in African women..  26:617-624. 2012

Reply to 'pharmacokinetic concerns related to darunavir/ritonavir plus raltegravir combination therapy trial'.  26:397-398. 2012

The association between Mycoplasma genitalium and HIV-1 acquisition in African women.  26:617-624. 2012

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).  25:2113-2122. 2011

IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation.  25:2099-2104. 2011

Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.  25:1489-1496. 2011

Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy.  25:691-700. 2011

Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.  25:185-195. 2011

Virologic and immunologic response to HAART, by age and regimen class.  24:2469-2479. 2010

Periconception pre-exposure prophylaxis to prevent HIV transmission: Benefits, risks, and challenges to implementation.  24:1975-1982. 2010

Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy.  24:1717-1726. 2010

Outcomes after virologic failure of first-line ART in South Africa.  24:1007-1012. 2010

A genome-wide association study of carotid atherosclerosis in HIV-infected men.  24:583-592. 2010

Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection.  24:573-582. 2010

A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.  24:447-455. 2010

HIV-1 infection of macrophages is dependent on evasion of innate immune cellular activation.  23:2255-2263. 2009

Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements..  23:2199-2208. 2009

Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study.  23:1539-1546. 2009

HIV viremia and changes in kidney function.  23:1089-1096. 2009

Host genetics and HIV-1 viral load set-point in African-Americans.  23:673-677. 2009

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.  23:525-530. 2009

Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes..  23:2069-2077. 2009

Does short-term virologic failure translate to clinical events in antiretroviral- naive patients initiating antiretroviral therapy in clinical practice 2008

Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.  22:1951-1960. 2008

Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia.  22:1821-1827. 2008

Treatment response in acute/early infection versus advanced AIDS: Equivalent first and second phases of HIV RNA decline.  22:957-962. 2008

Association of antiretroviral therapy with fibrinogen levels in HIV-infection.  22:707-715. 2008

Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? The Antiretroviral Therapy Cohort Collaboration (ART-CC).  22:2481-2492. 2008

Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 Week results.  22:249-255. 2008

Immunological control of chronic HIV-1 infection: HLA-mediated immune function and viral evolution in adolescents.  21:2387-2397. 2007

Prevalence and factors associated with dry skin in HIV infection: The FRAM study.  21:2051-2057. 2007

Efficacy of boosted protease inhibitor monotherapy in patients with complex medical problems.  21:1821-1823. 2007

Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects.  21:1373-1375. 2007

Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe.  21:1027-1034. 2007

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.  21. 2007

Reduced lopinavir exposure during pregnancy.  20:1931-1939. 2006

Cohort- and time-specific associations of CTLA4 genotypes with HIV-1 disease progression.  20:1583-1590. 2006

Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity.  20:1521-1529. 2006

Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.  20:1109-1116. 2006

Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients.  20:353-360. 2006

Impact of pregnancy on abacavir pharmacokinetics.  20:553-560. 2006

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.  20:223-231. 2006

Monocyte derived dendritic cells from HIV-1 infected individuals partially reconstitute CD4 T-cell responses.  20:171-180. 2006

A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers.  19:1289-1297. 2005

Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia.  19:1309-1315. 2005

Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy.  19:1059-1063. 2005

Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals.  19:381-389. 2005

CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides.  19:241-250. 2005

Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.  19:145-152. 2005

Determinants of HIV drug resistance mutations in plasma virus after treatment interruption.  19:2174-2175. 2005

Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count.  19:2038-2041. 2005

Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study.  18:2391-2400. 2004

Factors associated with chronic renal failure in HIV-infected ambulatory patients..  18:2171-2178. 2004

Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings.  18:939-943. 2004

Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine.  17:1659-1665. 2003

Human papillomavirus infection and abnormal cytology of the anus in HIV-infected and uninfected adolescents.  17:311-320. 2003

The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy..  17 Suppl 4. 2003

Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents.  16:2275-2284. 2002

Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy.  16:2129-2135. 2002

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.  16:579-588. 2002

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.  16:75-83. 2002

Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).  15:1971-1978. 2001

Pneumocystis carinii pneumonia and cytomegalovirus infection in children with vertically acquired HIV infection.  15:335-339. 2001

Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients.  14:2869-2876. 2000

Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884.  14:2495-2501. 2000

Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: Results of adult AIDS clinical trials group protocol 370.  14:1553-1561. 2000

Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine.  14:1365-1374. 2000

Short tandem repeat methodology for genotypic identification of single-person versus multi-person use of syringes.  14:1507-1513. 2000

Partner type and condom use.  14:537-546. 2000

Neurological outcomes in late HIV infection: Adverse impact of neurological impairment on survival and protective effect of antiviral therapy.  13:1677-1685. 1999

Predictors of optimal virological response to potent antiretroviral therapy.  13:1873-1880. 1999

Cerebrospinal fluid S-100b concentrations in patients with HIV infection [4].  13:139-140. 1999

HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women [10].  13:1990-1991. 1999

Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents.  13:1629-1635. 1999

Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults.  12. 1998

Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team..  12:F203-F209. 1998

The new HIV therapies: Implications for HIV prevention [6].  12:117-118. 1998

Cerebral proton magnetic resonance spectroscopy in asymptomatic HIV infection.  11:289-295. 1997

Atovaquone is effective treatment for the symptoms of gastrointestinal microsporidiosis in HIV-1-infected patients.  10:619-623. 1996

Cerebral proton magnetic resonance spectroscopy in cytomegalovirus encephalitis and HIV leucoencephalopathy/encephalitis [9].  10:1443-1444. 1996

Vitamin A depletion in HIV infection and AIDS [10].  10:114. 1996

Persistent anaemia in HIV-infected individuals due to parvovirus B19 infection [6].  8:1191-1192. 1994

Seroconversion in patients attending sexually transmitted disease clinics.  8:351-355. 1994

Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction.  7. 1993

Expression of HIV-1 in the cerebrospinal fluid detected by the polymerase chain reaction and its correlation with central nervous system disease.  5:797-803. 1991

HTLV-I and HIV-1-associated neurologic abnormalities; syphilis as a confounding factor.  3:763-769. 1989

Reversible zidovudine-induced pure red-cell aplasia.  3:177-178. 1989